| |

New Resource on Mesothelioma Genomics

ByHolly Zink
New Resource on Mesothelioma Genomics

The MESOMICS project is the most comprehensive dataset of mesothelioma genomics to date. The data in this resource can help researchers to design precision treatments for mesothelioma patients

This project was created by an international collaboration between scientists from France, Chile, and the United States.

Understanding Diagnosis

Malignant pleural mesothelioma is a rare cancer caused by asbestos exposure. There are approximately 2,000 cases of mesothelioma diagnosed in the United States alone every year. Because it is so rare, the treatment options are very limited compared to other types of cancer.

The limited treatment options combined with the cancer’s ability to spread without being noticed makes mesothelioma a deadly disease. Median overall survival for mesothelioma patients is a little over a year.

One factor in the prognosis for mesothelioma is the cell type. There are three cell types for this type of cancer: epithelioid, sarcomatoid and biphasic. Epithelioid mesothelioma tends to have the best prognosis. Sarcomatoid mesothelioma usually has the worst prognosis.

Deciding on Treatment Plan

One of the ways doctors decide on a treatment plan for mesothelioma patients is by looking at the cancer tissue and identifying important characteristics. Things like cell type and biomarkers can tell doctors what type of treatment will work best for the patient.

However, the rareness of mesothelioma can make this strategy hard for doctors. There isn’t enough research for doctors to be able to agree on a standard approach for treating mesothelioma.

That’s where the MESOMICS project comes in. This dataset combines the tumor profiles of over 100 malignant pleural mesothelioma tumors. Now researchers can use this data to analyze the genomic structure of mesothelioma and identify specific structures that could impact treatment.

“As most patients with MPM will survive to second- or third-line systemic therapy, future studies will be needed to describe the molecular landscape of MPM at these time points to develop effective precision medicine strategies,” say study researchers.

Source

Di Genova A, Mangiante L, Sexton-Oates A, et al. A molecular phenotypic map of malignant pleural mesothelioma. Gigascience. 2022;12:giac128. doi: 10.1093/gigascience/giac128. https://pubmed.ncbi.nlm.nih.gov/36705549

Similar Posts

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Micro-RNAs May Offer New Way to Fight Mesothelioma

    ByAlex Strauss

    Scientists at one of the world’s top mesothelioma research centers, the Asbestos Diseases Research institute in Sydney, Australia, say that restoring the expression of certain micro RNAs in the cells of mesothelioma patients may offer a new way to fight the disease. A microRNA is a small RNA molecule which is involved in the regulation of gene expression. According to a new report in the Annals of Oncology, the Australian scientists found reduced expression of the micro RNA-15 family (miR-15/16) in the cells of mice with mesothelioma. “When malignant pleural mesothelioma cell lines were compared with the normal mesothelial cell line MeT-5A, the downregulation of miR-15/16 was 2- to 10-fold,” they report. This finding is consistent with previous cancer research…

  • |

    Mesothelioma Still Carries Heavy Mortality Burden in U.S.

    ByAlex Strauss

    Asbestos exposure cost Americans more than 427,000 years of potential life in the first decade of the new millennium. That figure comes from a study on mesothelioma and asbestosis – the two most deadly asbestos-related diseases – conducted by the CDC’s National Institute for Occupational Safety and Health (NIOSH). Using National Center for Health Statistics mortality data, NIOSH researchers evaluated premature deaths and “loss of potentially productive years of life” attributable to either asbestosis or mesothelioma between 1999 and 2010. The data included only people 25 years or older with an underlying cause of death listed on their death certificate of either asbestosis or malignant mesothelioma. When the figures were calculated using the normal life expectancy for each asbestosis victim…

  • | |

    Treatment Uses Herpes Virus to Shrink Mesothelioma Tumors

    ByAlex Strauss

    Researchers at a hospital in Sheffield, England are testing a potential new mesothelioma treatment based on the same virus that causes herpes. The small-scale trial is the first in the world to test the modified herpes simplex virus, HSV1716, in human mesothelioma patients. HSV1716 has been genetically engineered to infect and kill cancer cells without harming healthy cells. In laboratory studies on mesothelioma and some other cancers, it has been shown to be effective at shrinking tumors while causing limited toxicity. Just as significantly, HSV1716 increased survival rates among mice with various human cancers. The Phase I/II trial at Sheffield Experimental Cancer Medicine Centre is the next stage in development of HSV1716 as a viable mesothelioma treatment. The goal of…

  • | |

    New Mesothelioma Drug Kills Cancer Stem Cells

    ByAlex Strauss

    Citing “significant enthusiasm within the mesothelioma community”, the manufacturers of a promising new mesothelioma drug say they have begun a major test of the drug in patients. Massachusetts-based Verastem, Inc. focuses on drugs that fight cancer by attacking the stem cells that give rise to them. Earlier this summer, the FDA granted orphan drug status to their stem cell inhibitor, defactinib, for the treatment of mesothelioma. The designation, which is reserved for drugs that fight the rarest of diseases, helps pave the way for testing and faster approval, depending on the results of clinical trials. “Development of a drug that preferentially kills cancer stem cells is a promising approach, as many standard-of-care treatments have been shown to either have no…

  • | |

    Mesothelioma Study Finds New Treatment Target

    ByAlex Strauss

    Immunotherapy, which involves reprogramming T-cells to find and attack cancer cells, is one of the fastest-growing areas of cancer research. One of the biggest challenges of immunotherapy is how to harness the power of T-cells against cancer without also turning them against healthy cells. A new study conducted in Switzerland and published in the Journal of Translational Medicine addressed the problem by reprogramming T-cells to recognize and attack mesothelioma cells that express a specific protein. Fibroblast Activation Protein (FAP) is expressed on the surface of tumor-associated fibroblast cells which are found in the connective tissue of mesothelioma tumors. FAP is also found in mesothelioma cells and may play a role in the start of cancer, as well as the growth…